Table 3.

Age- and sex-adjusted mortality rates and HRs for different exposure groups

ExposurePerson (y)Death (N)IR (95% CI) per 100 pysHR (95% CI) compared with participants without VTE and without cancerHR (95% CI) compared with participants without VTE and without cancer, after correction for confounders HR (95% CI) compared with participants with cancer but without VTEHR (95% CI) compared with participants with cancer but without VTE, after correction for confounders 
No VTE, no cancer 1 624 840 10 341 0.64 (0.62-0.65) 1 (reference) 1 (reference) N/A N/A 
VTE 8993 448 5.0 (4.6-5.5) 3.2 (2.9-3.5) 3.2 (2.9-3.5)   
Cancer 65 018 6002 9.2 (9.0-9.5) 7.2 (7.0-7.4) 7.2 (6.9-7.4) 1 (reference) 1 (reference) 
Cancer-related VTE 889 403 45.3 (41.1-50.0) 24.6 (22.2-27.2) 25.4 (22.9-28.1) 3.4 (3.1-3.8) 3.5 (3.2-3.9) 
ExposurePerson (y)Death (N)IR (95% CI) per 100 pysHR (95% CI) compared with participants without VTE and without cancerHR (95% CI) compared with participants without VTE and without cancer, after correction for confounders HR (95% CI) compared with participants with cancer but without VTEHR (95% CI) compared with participants with cancer but without VTE, after correction for confounders 
No VTE, no cancer 1 624 840 10 341 0.64 (0.62-0.65) 1 (reference) 1 (reference) N/A N/A 
VTE 8993 448 5.0 (4.6-5.5) 3.2 (2.9-3.5) 3.2 (2.9-3.5)   
Cancer 65 018 6002 9.2 (9.0-9.5) 7.2 (7.0-7.4) 7.2 (6.9-7.4) 1 (reference) 1 (reference) 
Cancer-related VTE 889 403 45.3 (41.1-50.0) 24.6 (22.2-27.2) 25.4 (22.9-28.1) 3.4 (3.1-3.8) 3.5 (3.2-3.9) 

N/A, not available.

Note, extra confounders corrected for were smoking, body mass index, diabetes, and antihypertensive medicine use.